Via: thefly.com
Silk Road Medical shares are up in afternoon trading after the company announced last night that "positive" results from the ongoing TransCarotid Artery Revascularization, or TCAR, Surveillance Project comparing TCAR and transfemoral carotid artery stenting, or TF-CAS, were published in The Journal of the American Medical Association, or JAMA. The study evaluated patients who underwent carotid procedures between 2016 and 2019, with 5,251 patients receiving TCAR compared to 6,640 patients receiving TF-CAS, with 3,286 patients in each group analyzed using propensity score matching. TCAR was associated with significantly lower rates of in-hospital stroke or death as well as the individual rates of stroke and death, the company stated. Additionally, there were no statistical differences noted between TCAR and TF-CAS for in-hospital myocardial infarction, according to Silk Road. "These results showed a significantly lower risk of stroke or death for TCAR versus TF-CAS and further contribute to the groundswell of clinical evidence showing the benefits of TCAR. I am confident that the growing evidence base coupled with publication of these data in JAMA, a peer-reviewed journal, will incrementally drive TCAR towards standard of care," Dr. Schermerhorn of Beth Israel Deaconess Medical Center was quoted as having said in the company's press release. In afternoon trading, Silk Road Medical shares are up $1.99, or 5.5%, to $38.01.
Read More: https://thefly.com/n.php?id=3008812
RSS Feed
